share_log

Sera Prognostics | 10-Q: Q2 2024 Earnings Report

Sera Prognostics | 10-Q: Q2 2024 Earnings Report

Sera Prognostics | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/07 12:22

Moomoo AI 已提取核心訊息

Sera Prognostics reported Q2 2024 financial results with revenue of $24,000 and a net loss of $8.3 million, compared to $123,000 revenue and $10.5 million net loss in Q2 2023. Operating expenses decreased to $9.3 million from $11.6 million year-over-year, driven by reduced selling and marketing costs of $1.8 million and general administrative expenses of $1.2 million.The company maintained a strong financial position with $80.9 million in cash, cash equivalents and marketable securities as of June 30, 2024. Research and development expenses increased by $0.7 million to $4.4 million, primarily due to increased product development activities. The company believes its existing financial resources are sufficient to fund operations into 2027.On August 7, 2024, Sera entered into a $50 million at-the-market equity offering agreement with TD Cowen. The company's PRIME study enrollment was stopped in December 2023 due to efficacy at interim analysis, with final analysis expected in fall 2024. Management continues to focus on accelerating market adoption of its PreTRM test while developing additional pipeline products.
Sera Prognostics reported Q2 2024 financial results with revenue of $24,000 and a net loss of $8.3 million, compared to $123,000 revenue and $10.5 million net loss in Q2 2023. Operating expenses decreased to $9.3 million from $11.6 million year-over-year, driven by reduced selling and marketing costs of $1.8 million and general administrative expenses of $1.2 million.The company maintained a strong financial position with $80.9 million in cash, cash equivalents and marketable securities as of June 30, 2024. Research and development expenses increased by $0.7 million to $4.4 million, primarily due to increased product development activities. The company believes its existing financial resources are sufficient to fund operations into 2027.On August 7, 2024, Sera entered into a $50 million at-the-market equity offering agreement with TD Cowen. The company's PRIME study enrollment was stopped in December 2023 due to efficacy at interim analysis, with final analysis expected in fall 2024. Management continues to focus on accelerating market adoption of its PreTRM test while developing additional pipeline products.
Sera Prognostics報告了2024年第二季度的財務結果，營業收入爲24,000美元，淨虧損爲830萬，相比於2023年第二季度的123,000美元營業收入和1050萬淨虧損。營業費用同比減少至930萬，較1160萬，主要由於銷售和市場費用減少了180萬，以及一般管理費用減少了120萬。截至2024年6月30日，公司保持強勁的財務狀況，現金、現金等價物和可交易證券達8090萬。研發費用增加了70萬，達到440萬，主要是由於產品開發活動增加。公司認爲其現有的財務資源足以支持運營到2027年。2024年8月7日，Sera與TD Cowen簽訂了一項5000萬的市場增發協議。由於中期分析顯示有效性，該公司的PRIME研究入組於2023年12月停止，最終分析預計將在2024年秋季進行。管理層繼續專注於加速其PreTRm測試的市場採用，同時開發更多的潛在產品。
Sera Prognostics報告了2024年第二季度的財務結果，營業收入爲24,000美元，淨虧損爲830萬，相比於2023年第二季度的123,000美元營業收入和1050萬淨虧損。營業費用同比減少至930萬，較1160萬，主要由於銷售和市場費用減少了180萬，以及一般管理費用減少了120萬。截至2024年6月30日，公司保持強勁的財務狀況，現金、現金等價物和可交易證券達8090萬。研發費用增加了70萬，達到440萬，主要是由於產品開發活動增加。公司認爲其現有的財務資源足以支持運營到2027年。2024年8月7日，Sera與TD Cowen簽訂了一項5000萬的市場增發協議。由於中期分析顯示有效性，該公司的PRIME研究入組於2023年12月停止，最終分析預計將在2024年秋季進行。管理層繼續專注於加速其PreTRm測試的市場採用，同時開發更多的潛在產品。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    BIOSIG TECHNOLOGIES INC
    BSGM
    -- 1.0300
    Sensus Healthcare
    SRTS
    -- 8.235
    Helius Medical Technologies
    HSDT
    -- 0.7500
    Adagio Medical
    ADGM
    -- 1.170
    Xtant Medical
    XTNT
    -- 0.6149
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！